The FDA Just Carpet-Bombed 25 Telehealth Companies Over Knockoff Ozempic
The FDA just hit 25 telehealth companies with warning letters for marketing compounded knockoffs of Ozempic and Mounjaro with bogus claims. It's the third enforcement wave in under a year, with over 100 total letters sent, and the real numbers on patient harm are alarming.
Imagine walking into a restaurant that advertises "same recipe as Michelin-starred Chef Thomas Keller" on the menu, except the kitchen has never been inspected, nobody checked the ingredients, and the chef learned to cook from YouTube. That's roughly what dozens of telehealth companies have been doing with compounded versions of blockbuster weight-loss drugs. And the FDA just said: enough.
During the week of June 15, the agency fired off 25 warning letters to telehealth firms for false and misleading marketing of compounded semaglutide and tirzepatide, the active ingredients in Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound. It's the third wave of enforcement letters in less than a year, bringing the total north of 100. The message is clear: the era of Wild West GLP-1 marketing is over.
What Got These Companies in Trouble
The violations read like a playbook of creative half-truths.
Some telehealth sites described their compounded products as "generic Wegovy" or "generic Ozempic." That sounds reasonable to a consumer, but it's flatly wrong. Generic drugs go through an FDA approval process. Compounded drugs do not. Calling a compounded injection "generic" is like calling your cousin's homebrew "Budweiser."
Others went further, claiming their products were "clinically proven to deliver the same results" as FDA-approved versions, or that they came from "FDA-approved pharmacies." The FDA doesn't approve or license compounding pharmacies in any meaningful sense. Those claims are essentially made up.
Perhaps the sneakiest move: telehealth companies slapped their own logos and branding on the products, making it look like they manufactured the drugs. In reality, a separate compounding pharmacy made them. Consumers had no idea who actually mixed their injections.
The FDA used its "misleading net impression" standard to catch companies that technically avoided lying but arranged their websites to create a false picture. Think of it like a dating profile where every photo is technically you, but collectively they suggest you're a different person entirely.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Three Waves, One Hundred Letters, Zero Patience
This crackdown didn't start in June. It's been building for nearly a year.
The first salvo came in September 2025, when the FDA sent roughly 50 warning letters to telehealth and pharma firms over misleading GLP-1 advertising. Then in March 2026, another 30 letters went out, specifically targeting "sameness" claims and obscured sourcing. Now the June wave adds 25 more, focused squarely on consumer-facing promotion.
Reporters identified a handful of the latest recipients, including Medica Weight Loss, Ready Med, Clover Meds, and Maxim Health Inc. The full list sits in the FDA's warning letter database for anyone willing to dig.
Each company got 15 business days to explain how they'll fix the problem. This isn't a polite suggestion anymore.
The Backstory: How Compounded GLP-1s Became a $Billion Gray Market
To understand why this matters, you need to rewind to 2022.
When Wegovy and Ozempic took off, Novo Nordisk couldn't make them fast enough. Same story for Lilly's Mounjaro, which hit the shortage list in December 2022. The FDA has a rule for situations like this: when an approved drug is in shortage, compounding pharmacies can legally make copies. It's a safety valve designed to keep patients from going without critical medications.
But what started as a safety valve became a fire hose. Telehealth startups saw an opportunity. They partnered with compounding pharmacies, built slick websites, and offered "affordable" semaglutide and tirzepatide to anyone with a credit card and a brief online consultation. The GLP-1 gold rush was on.
Then the shortages ended. The FDA resolved the tirzepatide shortage in October 2024 and semaglutide in February 2025. Compounders were given 60 to 90 days to wind down production. Many didn't.
In April 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list entirely. If finalized, that would block outsourcing facilities (the large-scale compounders) from using raw API to make these drugs at all, except in narrow, clinically justified cases. The legal foundation for mass-market compounded GLP-1s is crumbling.
The Patient Safety Problem Nobody Wants to Talk About
This isn't just about marketing fraud. People are getting hurt.
As of May 31, 2026, the FDA has received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. An earlier snapshot from September 2025 counted 329 hospitalizations and 23 deaths across all compounded GLP-1 products. And the FDA openly admits these numbers are probably low, because many compounding pharmacies aren't even required to report adverse events.
The single biggest culprit? Dosing errors. Compounded injectables often come in multi-dose vials that patients measure themselves with syringes, rather than the click-to-dose pens that Novo and Lilly sell. Some patients accidentally gave themselves ten times the intended dose, landing in the emergency room with severe nausea, vomiting, dehydration, and pancreatitis.
Lilly didn't mince words about this. In an open letter, the company warned that compounded tirzepatide mixed with vitamin B12, glycine, and other additives constitutes an untested combination drug with unknown risks. Lilly said it tested market samples and found "worrisome quality issues." The company called on the FDA to "take decisive action against the mass distribution of illegally compounded anti-obesity drugs."
That's a pharmaceutical giant essentially saying: these knockoffs are dangerous, and we want them gone. Self-interest? Absolutely. But the adverse event data backs up the concern.
Why Novo and Lilly Are Quietly Celebrating
Both companies have their own regulatory headaches. The FDA dinged Novo Nordisk and Eli Lilly in September 2025 over a celebrity-hosted promotional video that allegedly downplayed serious risks of their branded drugs, including thyroid cancer warnings and GI side effects. So neither company is wearing a halo here.
But the compounding crackdown is structurally a gift to both franchises.
Every patient who can't get compounded semaglutide becomes a potential customer for Wegovy or Ozempic. Every shuttered telehealth GLP-1 operation pushes demand toward Mounjaro and Zepbound. Analysts expect the enforcement campaign to improve demand capture and pricing power for branded products as compounded supply dries up.
Novo Nordisk is already capitalizing on the moment. In March 2026, the company struck a deal with Hims & Hers, the biggest telehealth player in weight loss. Under the agreement, Hims & Hers will offer Novo's branded semaglutide products through its platform while scaling back advertising of compounded GLP-1s. It's a masterful judo move: turn your biggest gray-market competitor into a distribution partner.
Lilly hasn't announced a similar telehealth partnership yet, but the playbook is obvious. Expect more deals like this as telehealth companies realize that selling branded drugs (with proper prescriptions and insurance billing) beats fighting the FDA.
What Happens Next
The telehealth industry faces an identity crisis. Companies that built their business models around cheap compounded GLP-1s have three options: pivot to branded prescribing, diversify into other services, or fight the FDA and risk criminal referrals. Most will choose door number one.
For patients, the picture is mixed. The crackdown protects people from sketchy, unregulated injections. But it also removes a lower-cost option for the millions of Americans who can't afford branded GLP-1s (which can run over $1,000 per month without insurance). Some experts worry that cutting off compounded supply could push desperate patients toward even riskier channels, including counterfeit products from overseas.
The FDA's proposed exclusion of GLP-1s from the 503B bulks list is still working its way through the regulatory process. If finalized, it would be the nail in the coffin for large-scale compounding. Small 503A pharmacies could still compound for individual patients with documented medical needs (like an allergy to an inactive ingredient in the branded product), but the days of mass-produced compounded Ozempic are numbered.
One hundred warning letters. Hundreds of hospitalizations. Billions of dollars in branded drug sales at stake. The FDA's message to telehealth firms is simple: if you want to play in the GLP-1 market, play by the rules. Or don't play at all.
Science & Discovery
5 min read
Jennifer Doudna Just Built CRISPR Enzymes That Evolution Never Imagined
Jennifer Doudna's team used AI to design gene-editing enzymes that don't exist in nature, and they work in human cells. The implications for CRISPR's future (and its messy patent landscape) could be enormous.
